USA - NASDAQ:AVTX - US05338F3064 - Common Stock
AVTX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVTX as it has an excellent financial health rating, but there are worries on the profitability. AVTX is quite expensive at the moment. It does show a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.34% | ||
| ROE | -46.84% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 201.13% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.44 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 19.96 | ||
| Quick Ratio | 19.96 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
17.57
-0.35 (-1.95%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 523.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.74 | ||
| P/tB | 1.89 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.34% | ||
| ROE | -46.84% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 201.13% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 19.96 | ||
| Quick Ratio | 19.96 | ||
| Altman-Z | 4.44 |
ChartMill assigns a fundamental rating of 4 / 10 to AVTX.
ChartMill assigns a valuation rating of 1 / 10 to AVALO THERAPEUTICS INC (AVTX). This can be considered as Overvalued.
AVALO THERAPEUTICS INC (AVTX) has a profitability rating of 2 / 10.
The Earnings per Share (EPS) of AVALO THERAPEUTICS INC (AVTX) is expected to grow by 96.35% in the next year.